Endothelial dysfunction and cardiovascular risk factors

Diabetes Research and Clinical Practice

Volumn 84, Issue 1, 2009, Pages 1-10

  Grover Páez, Fernando ^a   Zavalza Gómez, Ana Bertha ^a  

^a Hospital of Obstetrics and Gynecology   (Mexico)

Author keywords

Coronary risk factors; Endothelial dysfunction; Endothelium; Nitric oxide; Therapeutic interventions

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; ANTIOXIDANT; ASCORBIC ACID; BIOLOGICAL MARKER; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; GLYCERYL TRINITRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; INSULIN; INSULIN GLARGINE; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SALBUTAMOL; TETRAHYDROBIOPTERIN;

ANTIHYPERTENSIVE THERAPY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTERIAL STIFFNESS; ARTERY DIAMETER; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL TONE; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC INFLAMMATION; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET THERAPY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ESTROGEN THERAPY; FUNCTION TEST; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; INSULIN TREATMENT; LEUKOCYTE ADHERENCE; METABOLIC REGULATION; MITOGENESIS; NEOVASCULARIZATION (PATHOLOGY); NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE PROCEDURE; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL CIRCULATION; PERIPHERAL VASCULAR SYSTEM; PHYSICAL ACTIVITY; REVIEW; SITTING; SMOKING; STROKE; THROMBOCYTE FUNCTION; THROMBOSIS; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASOCONSTRICTION; VASODILATATION;

ANTICHOLESTEREMIC AGENTS; ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; NITRIC OXIDE; RISK FACTORS;

EID: 62049085337     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2008.12.013     Document Type: Review

References (69)

1. Vita J.A., and Keaney J.F. Endothelial function: a barometer for cardiovascular risk?. Circulation 106 (2002) 640-642
2. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362 (1993) 801-809
3. Schechter A.N., and Gladwin M.T. Hemoglobin and the paracrine and endocrine functions of nitric oxide. N. Engl. J. Med. 348 (2003) 1483-1485
4. Furchgott R.F., and Zawadzki J.V. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288 (1980) 373-376
5. Forstermann U., and Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 113 (2006) 1708-1714
6. Govers R., and Rabelink T.J. Cellular regulation of endothelial nitric oxide synthase. Am. J. Physiol. Renal. Physiol. 280 (2001) F193-F206
7. Busse R., Edwards G., Feletou M., Fleming I., Vanhoutte P.M., and Weston A.H. EDHF: bringing the concepts together. Trends Pharmacol. Sci. 3 (2002) 374-380
8. Halcox J.P., Narayanan S., Cramer-Joyce L., Mincemoyer R., and Quyyumi A. Characterization of endothelium-derived hyperpolarizing factor in the human forearm microcirculation. Am. J. Physiol. Heart Circ. Physiol. 280 (2001) H2470-H2477
9. Aird W.C. Spatial and temporal dynamics of the endothelium. J. Thromb. Haemost. 3 (2005) 1392-1406
10. Massimo V., Lorenzo C., and Francesco C. Effects of Olmesartan on endothelial function. High Blood Pressure Cardiov. Prev. 14 4 (2007) 221-227
11. Endemann D.H., and Schiffrin E.L. Endothelial dysfunction. J. Am. Soc. Nephrol. 15 (2004) 1983-1992
12. Schachinger V., Britten M.B., and Zeiher A.M. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101 (2000) 1899-1906
13. Behrendt D., and Ganz P. Endothelial function: from vascular biology to clinical applications. Am. J. Cardiol. 90 (2002) 40L-48L
14. Libby P., Ridker P.M., and Maseri A. Inflammation in atherosclerosis. Circulation 105 (2002) 1135-1143
15. Tedgui A., and Mallat Z. Anti-inflammatory mechanisms in the vascular wall. Circ. Res. 88 (2001) 877-887
16. Cheng C., Tempel D., van Haperen R., Van Der Baan A., Grosveld F., Daemen M.J., et al. Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation 113 (2006) 2744-2753
17. Ishizuka T., Takamizawa-Matsumoto M., Suzuki K., and Kurita A. Endothelin-1 enhances vascular cell adhesion molecule-1 expression in tumor necrosis factor alpha-stimulated vascular endothelial cells. Eur. J. Pharmacol. 369 (1999) 237-245
18. Li H., Cybulsky M.I., Gimbrone Jr. M.A., and Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine regulatable mononuclear leukocyte adhesion molecule, in rabbit endothelium. Arterioscler. Thromb. 13 (1993) 197-204
19. Cybulsky M.I., Iiyama K., Li H., Zhu S., Chen M., Iiyama M., et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J. Clin. Invest. 107 (2001) 1255-1262
20. Lee R.T., Yamamoto C., Feng Y., Potter-Perigo S., Briggs W.H., Landschulz K.T., et al. Mechanical strain induces specific changes in the synthesis and organization of proteoglycans by vascular smooth muscle cells. J. Biol. Chem. 276 (2001) 13847-13851
21. Quehenberger P., Bierhaus A., Fasching P., Muellner C., Klevesath M., Hong M., et al. Endothelin 1 transcription is controlled by nuclear factor-kappaB in AGE-stimulated cultured endothelial cells. Diabetes 49 (2000) 1561-1570
22. Schneider J.G., Tilly N., Hierl T., Sommer U., Hamann A., Dugi K., et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am. J. Hypertens. 15 (2002) 967-972
23. Cosentino F., and Luscher T.F. Endothelial dysfunction in diabetes mellitus. J. Cardiovasc. Pharmacol. 32 Suppl. 3 (1998) S54-S61
24. Huszka M., Kaplar M., Rejto L., Tornai I., Palatka K., Laszlo P., et al. The association of reduced endothelium derived relaxing factor-NO production with endothelial damage and increased in vivo platelet activation in patients with diabetes mellitus. Thromb. Res. 86 (1997) 173-180
25. Huvers F.C., De Leeuw P.W., Houben A.J., De Haan C.H., Hamulyak K., Schouten H., et al. Endothelium-dependent vasodilatation, plasma markers of endothelial function, and adrenergic vasoconstrictor responses in type 1 diabetes under near-normoglycemic conditions. Diabetes 48 (1999) 1300-1307
26. Lambert J., Aarsen M., Donker A.J., and Stehouwer C.D. Endothelium-dependent and independent vasodilation of large arteries in normoalbuminuric insulin-dependent diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 16 (1996) 705-711
27. O'Brien S.F., Watts G.F., Playaford D.A., Burke V., ONeal D.N., and Best J.D. Low-density lipoprotein size, high-density lipoprotein concentration, and endotelial dysfunction in non-insulin-dependent diabetes. Diab. Med. 14 (1997) 974-978
28. Deanfield J., Donald A., Ferri C., Giannattasio C., Halcox J., Halligan S., et al. Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part I. Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J. Hypertens. 23 (2005) 7-17
29. Huang P.L., Huang Z., Mashimo H., Kenneth D., Bloch M.A., Moskowitz J.A., et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377 (1995) 239-242
30. Bragulat E., de la Sierra A., Antonio M.T., and Coca A. Endothelial dysfunction in salt-sensitive essential hypertension. Hypertension 37 (2001) 444-448
31. Lüscher T.F. The endothelium and cardiovascular disease - a complex relation. N. Engl. J. Med. 330 (1994) 1081-1083
32. Masumoto A., Hirooka Y., Hironaga K., Eshima K., Setoguchi S., Egashira K., et al. Effect of pravastatin on endothelial function in patients with coronary artery disease (cholesterol-independent effect of pravastatin). Am. J. Cardiol. 88 (2001) 1291-1294
33. d'Uscio L.V., Baker T.A., Mantilla C.B., Smith L., Weiler D., Sieck G.C., et al. Mechanism of endothelial dysfunction in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1017-1022
34. Drexler H., Zeiher A.M., Köster W., Zeh W., Wieland H., et al. Endothelial dysfunction in the coronary circulation in hypercholsterolemia. Circulation 86 Suppl. I (1992) I-117
35. Verhaar M.C., Wever R.M.F., Kastelein J.J.P., Van Loon D., Milstien S., Koomans H.A., et al. Effects of oral folic acid supplementation on endothelial function in familial hypercholesterolemia: a randomized placebo-controlled trial. Circulation 100 (1999) 335-338
36. Matz R.L., and Andriantsitohaina R. Age-related endothelial dysfunction: potential implications for pharmacotherapy drugs. Aging 20 (2003) 527-550
37. Celermajer D.S., Sorensen K.E., Spiegelhalter D.S., Georgakopoulos D., Robinson J., and Deanfield J.E. Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J. Am. Coll. Cardiol. 24 (1994) 471-476
38. Urakami-Harasawa L., Shimokawa H., Nakashima M., Egashira K., and Takeshita A. Importance of endothelium-derived hyperpolarizing factor in human arteries. J. Clin. Invest. 100 (1997) 2793-2799
39. Celermajer D.S., Sorensen K.E., Georgakopoulos D., Bull C., Thomas O., Robinson J., et al. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 88 (1993) 2149-2155
40. Burke A.P., Farb A., Malcolm G.T., Liang Y.-h., Smialek J., and Virmani R. Coronary risk factors and plaque morphology in men with coronary artery disease who died suddenly. N. Engl. J. Med. 336 (1997) 1276-1282
41. Heitzer T., Just H., and Münzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers. Circulation 94 (1996) 6-9
42. Reilly M., Delanty N., Lawson J.A., and FitzGerald G.A. Modulation of oxidant stress in vivo in chronic cigarette smokers. Circulation 94 (1996) 19-25
43. Hingorani A.D., Cross J., Kharbanda R.K., Mullen M.J., Bhagat K., Taylor M., et al. Acute systemic inflammation impairs endothelium dependent dilatation in humans. Circulation 102 (2000) 994-999
44. Cleland S.J., Sattar N., Petrie J.R., Forouhi N.G., Elliott H.L., and Connell J.M.C. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin. Sci. (Colch) 98 (2000) 531-535
45. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., et al. International brachial artery reactivity task force. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J. Am. Coll. Cardiol. 39 (2002) 257-265
46. Joannides R., Bellien J., and Thuillez C. Clinical methods for the evaluation of endothelial function: a focus on resistance arteries. Fundam. Clin. Pharmacol. 20 (2006) 311-320
47. Hayward C.S., Kraidly M., Webb C.M., and Collins P. Assessment of endothelial function using peripheral waveform analysis: a clinical application. J. Am. Coll. Cardiol. 40 (2002) 521-528
48. Wilkinson I.B., Hall I.R., MacCallum H., Mackenzie I.S., McEniery C.M., van der Arend B.J., et al. Pulse-wave analysis: clinical evaluation of a noninvasive, widely applicable method for assessing endothelial function. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 147-152
49. Bonetti P.O., Pumper G.M., Higano S.T., Holmes Jr. D.R., Jeffrey T., and Kuvin A.L. Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J. Am. Coll. Cardiol. 44 (2004) 2137-2141
50. Naka K.K., Tweddel A.C., Doshi S.N., Goodfellow J., and Henderson A.H. Flow-mediated changes in pulse wave velocity: a new clinical measure of endothelial function. Eur. Heart J. 27 (2006) 302-309
51. Smith Jr. S.C., Anderson J.L., Cannon III R.O., Fadl Y.Y., Koenig W., Libby P., et al. CDC/AHA workshop on markers of inflammation and cardiovascular disease: application to clinical and public health practice: report from the clinical practice discussion group. Circulation 110 (2004) e550-e553
52. Ridker P.M., Brown N.J., Vaughan D.E., Harrison D.G., and Mehta J.L. Established and emerging plasma biomarkers in the prediction of first atherothrombotic events. Circulation 109 (2004) IV6-IV19
53. Vaughan D.E. PAI-1 and atherothrombosis. J. Thromb. Haemost. 3 (2005) 1879-1883
54. Meyer A.A., Kundt G., Steiner M., Schuff-Werner P., and Kienast W. Impaired flow-mediated vasodilation, carotid artery intima-media thickening, and elevated endothelial plasma markers in obese children: the impact of cardiovascular risk factors. Pediatrics 117 (2006) 1560-1567
55. Rifai N., and Ridker P.M. Inflammatory markers and coronary heart disease. Curr. Opin. Lipidol. 13 (2002) 383-389
56. Anderson T.J., Elstein E., Haber H., and Charbonneau F. Comparative study of ACE-inhibition, angiotensin-II antagonism and calcium-channel blockade on flow-mediated vasodilation in patients with coronary artery disease (BANFF-study). J. Am. Coll. Cardiol. 35 (1999) 60-66
57. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 342 (2000) 145-153
58. Nissen S.E., Tuzcu E.M., Schoenhagen P., Crowe T., Sasiela W.J., Tsai J., et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med. 352 (2005) 29-38
59. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 360 (2002) 7-22
60. O'Driscoll G., Green D., and Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 95 (1997) 1126-1131
61. Vita J.A., Yeung A.C., Winniford M., Hodgson J.M., Treasure C.B., Klein J.L., et al. Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 102 (2000) 846-851
62. Hambrecht R., Wolf A., Gielen S., Linke A., Hofer J., Erbs S., et al. Effect of exercise on coronary endothelial function in patients with coronary artery disease. N. Engl. J. Med. 342 (2000) 454-460
63. Williams J.K., and Adams M.R. Estrogens, progestins and coronary artery reactivity. Certain progestins may oppose the favorable effect of estrogen on the cardiovascular system in postmenopausal women. Nat. Med. 3 (1997) 273-274
64. Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. HEARS Research group. J. Am. Med. Assoc. 280 (1998) 605-613
65. Arcaro G., Cretti A., Balzano A., Lechi A., Muggeo M., Bonora E., et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation 105 (2002) 576-582
66. Rask-Madsen N., Ihlemann T., Krarup E., Christiansen E., Kober L., Nervil Kistorp C., et al. Insulin therapy improves insulin-stimulated endothelial function in patients with type 2 diabetes and ischemic heart disease. Diabetes 50 (2001) 2611-2618
67. Paolisso G., and Giugliano D. Oxidative stress and insulin action: is there a relationship?. Diabetologia 39 (1996) 357-363
68. Vehkavaara S., and Yki-Jarvinen H. 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 24 (2001) 325-330
69. Pistrosch F., Passauer J., Fischer S., Fuecker K., Hanefeld M., and Gross P. In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control. Diabetes Care 27 (2004) 484-490